SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz speaks as US President Donald Trump looks on during an event on drug pricing on February 5, 2026 in Washington, DC.
(Photo by Nathan Howard/Getty Images)
As TrumpRx Scam Does Virtually Nothing, Big Pharma Jacks Up Prices on Cancer Drugs
"As they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them, and patients are paying the price."
Mar 23, 2026
A report released Monday found that Big Pharma has continued raising prices on dozens of cancer drugs, despite President Donald Trump's repeated false claims that he and his administration have slashed drug prices by a mathematically impossible 600%.
The analysis, conducted by Patients for Affordable Drugs, found that pharmaceutical companies increased prices on 64 oncology drugs in the first weeks of 2026, with the vast majority of price hikes coming in above the rate of inflation.
Patients for Affordable Drugs noted the heavy financial toll that paying for treatments takes on US cancer patients, and said the latest price increases would only exacerbate the crisis.
"Cancer drugs are among the most expensive drugs on the market, costing $74,000 more on average than non-cancer drugs," the group explained. "More than 42% of cancer patients in the US fully depleted their savings within two years of diagnosis to cover their care. More than half of Americans with cancer go into debt because of the cost of their care."
Making matters worse, the group added, is that Big Pharma is heavily lobbying Congress to pass legislation that would further delay small molecule drugs, including "widely used, high-cost cancer treatments," from becoming eligible for Medicare price negotiations.
Merith Basey, CEO of Patients for Affordable Drugs, stressed that the latest price increases were unacceptable given that "cancer is a leading cause of death among American seniors, and the treatments patients rely on are already among the most expensive."
"Yet as they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them," added Basey, "and patients are paying the price."
While the Patients for Affordable Drugs report focuses on cancer drugs, a December report from Reuters found that at least 350 branded medications are set for price hikes in 2026, including “vaccines against Covid, RSV, and shingles,” as well as the “blockbuster cancer treatment Ibrance.”
The total projected number of drugs seeing price increases in 2026 is significantly higher than in 2025, when 3 Axis Advisors estimated that pharmaceutical companies raised prices on 250 medications. The median price increase for drugs in 2026 is projected at 4%, roughly the same as in 2025.
All of these price increases have come despite Trump's false claims that he has lowered the prices of drugs to the point where pharmaceutical companies would actually be paying patients to take them.
An analysis released last week by the Center for American Progress (CAP) found that the president's TrumpRx initiative, which was created to purportedly offer Americans cheaper prescription drugs, offered genuinely lower prices on "exactly one" of the 54 medications listed on its website.
CAP also found that nearly one-third of the drugs available on the TrumpRx website have generic alternatives that were cheaper than what was being offered, and that the website made no mention of this.
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
A report released Monday found that Big Pharma has continued raising prices on dozens of cancer drugs, despite President Donald Trump's repeated false claims that he and his administration have slashed drug prices by a mathematically impossible 600%.
The analysis, conducted by Patients for Affordable Drugs, found that pharmaceutical companies increased prices on 64 oncology drugs in the first weeks of 2026, with the vast majority of price hikes coming in above the rate of inflation.
Patients for Affordable Drugs noted the heavy financial toll that paying for treatments takes on US cancer patients, and said the latest price increases would only exacerbate the crisis.
"Cancer drugs are among the most expensive drugs on the market, costing $74,000 more on average than non-cancer drugs," the group explained. "More than 42% of cancer patients in the US fully depleted their savings within two years of diagnosis to cover their care. More than half of Americans with cancer go into debt because of the cost of their care."
Making matters worse, the group added, is that Big Pharma is heavily lobbying Congress to pass legislation that would further delay small molecule drugs, including "widely used, high-cost cancer treatments," from becoming eligible for Medicare price negotiations.
Merith Basey, CEO of Patients for Affordable Drugs, stressed that the latest price increases were unacceptable given that "cancer is a leading cause of death among American seniors, and the treatments patients rely on are already among the most expensive."
"Yet as they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them," added Basey, "and patients are paying the price."
While the Patients for Affordable Drugs report focuses on cancer drugs, a December report from Reuters found that at least 350 branded medications are set for price hikes in 2026, including “vaccines against Covid, RSV, and shingles,” as well as the “blockbuster cancer treatment Ibrance.”
The total projected number of drugs seeing price increases in 2026 is significantly higher than in 2025, when 3 Axis Advisors estimated that pharmaceutical companies raised prices on 250 medications. The median price increase for drugs in 2026 is projected at 4%, roughly the same as in 2025.
All of these price increases have come despite Trump's false claims that he has lowered the prices of drugs to the point where pharmaceutical companies would actually be paying patients to take them.
An analysis released last week by the Center for American Progress (CAP) found that the president's TrumpRx initiative, which was created to purportedly offer Americans cheaper prescription drugs, offered genuinely lower prices on "exactly one" of the 54 medications listed on its website.
CAP also found that nearly one-third of the drugs available on the TrumpRx website have generic alternatives that were cheaper than what was being offered, and that the website made no mention of this.
From Your Site Articles
- Big Pharma Has Raised Drug Prices 1,186 Times This Year, Analysis Shows ›
- 'This Is Simply Price Gouging': Cost of Cancer Drug Hiked 1,400% Since 2013 ›
- Report Shows How Big Pharma Is Price Gouging Cancer Patients ›
- Opinion | Trump Joins the War on Cancer... on the Side of Cancer | Common Dreams ›
Related Articles Around the Web
A report released Monday found that Big Pharma has continued raising prices on dozens of cancer drugs, despite President Donald Trump's repeated false claims that he and his administration have slashed drug prices by a mathematically impossible 600%.
The analysis, conducted by Patients for Affordable Drugs, found that pharmaceutical companies increased prices on 64 oncology drugs in the first weeks of 2026, with the vast majority of price hikes coming in above the rate of inflation.
Patients for Affordable Drugs noted the heavy financial toll that paying for treatments takes on US cancer patients, and said the latest price increases would only exacerbate the crisis.
"Cancer drugs are among the most expensive drugs on the market, costing $74,000 more on average than non-cancer drugs," the group explained. "More than 42% of cancer patients in the US fully depleted their savings within two years of diagnosis to cover their care. More than half of Americans with cancer go into debt because of the cost of their care."
Making matters worse, the group added, is that Big Pharma is heavily lobbying Congress to pass legislation that would further delay small molecule drugs, including "widely used, high-cost cancer treatments," from becoming eligible for Medicare price negotiations.
Merith Basey, CEO of Patients for Affordable Drugs, stressed that the latest price increases were unacceptable given that "cancer is a leading cause of death among American seniors, and the treatments patients rely on are already among the most expensive."
"Yet as they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them," added Basey, "and patients are paying the price."
While the Patients for Affordable Drugs report focuses on cancer drugs, a December report from Reuters found that at least 350 branded medications are set for price hikes in 2026, including “vaccines against Covid, RSV, and shingles,” as well as the “blockbuster cancer treatment Ibrance.”
The total projected number of drugs seeing price increases in 2026 is significantly higher than in 2025, when 3 Axis Advisors estimated that pharmaceutical companies raised prices on 250 medications. The median price increase for drugs in 2026 is projected at 4%, roughly the same as in 2025.
All of these price increases have come despite Trump's false claims that he has lowered the prices of drugs to the point where pharmaceutical companies would actually be paying patients to take them.
An analysis released last week by the Center for American Progress (CAP) found that the president's TrumpRx initiative, which was created to purportedly offer Americans cheaper prescription drugs, offered genuinely lower prices on "exactly one" of the 54 medications listed on its website.
CAP also found that nearly one-third of the drugs available on the TrumpRx website have generic alternatives that were cheaper than what was being offered, and that the website made no mention of this.
From Your Site Articles
- Big Pharma Has Raised Drug Prices 1,186 Times This Year, Analysis Shows ›
- 'This Is Simply Price Gouging': Cost of Cancer Drug Hiked 1,400% Since 2013 ›
- Report Shows How Big Pharma Is Price Gouging Cancer Patients ›
- Opinion | Trump Joins the War on Cancer... on the Side of Cancer | Common Dreams ›
Related Articles Around the Web
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.